Health

STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 06/11/2026, 08:21:26 UTC.

Briefings

Revolution Medicines launched Rasonque, a pan-RAS inhibitor for pancreatic cancer, achieving a commercial debut with $198 million in sales within five weeks of U.S. approval. Over 5,000 patients have received the drug, and sales performance exceeded even bullish investor estimates, prompting a re-evaluation of future forecasts.

Key points

• Revolution Medicines achieved $198 million in sales for Rasonque within five weeks of U.S. approval.
• Over 5,000 patients have received Rasonque since the U.S. launch.

Context

Rasonque is a pan-RAS inhibitor for pancreatic cancer. The company's Chief Commercial Officer, Anthony Mancini, stated the launch was a strong start, with sales nearly double bullish estimates. Investors are now re-evaluating forecasts for what lies ahead.

Limitations

Sales figures are from a five-week period post-U.S. approval. The company did not provide specific sales data for the first five weeks, only the total five-week total. No specific patient demographics or geographic distribution are provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 15/11/2026, 10:31:07 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidpogpd3w35qyoy7aasy6aui2plsxi6zhy7ysvpurm3exfweuqqfq